In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissues

Journal of Diabetes and its Complications

Volumn 13, Issue 2, 1999, Pages 68-73

  Iannello, Silvia ^a   Cavaleri, Antonina ^a   Camuto, Massimo ^a   Belfiore, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; TOLRESTAT;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; ENZYME ACTIVITY; EYE; FEMALE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; LENS; NONHUMAN; OPTIC NERVE; PHOSPHORYLATION; PRIORITY JOURNAL; RABBIT;

ALDEHYDE REDUCTASE; ANIMALS; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; FEMALE; GLUCOSE; LENS, CRYSTALLINE; NAPHTHALENES; OPTIC NERVE; PHOSPHORYLATION; RABBITS;

EID: 0033031646     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(98)00027-0     Document Type: Article

References (54)

1. Belfiore F., Iannello S., Campione R., Volpicelli G. Capillaries phosphorylate glucose in a concentration-dependent manner through a glucokinase-like enzyme. A study in the eel Biochem Med Metab Biol. 43:1990;226-233.
2. Belfiore F., Iannello S., Campione R., Volpicelli G. Glucose metabolism in capillaries, Shafrir E. Frontiers in Diabetes Research. Lessons from Animal Diabetes III:1990;435-438 Smith-Gordon, London.
3. Belfiore F., Iannello S., Campione R., Volpicelli G. A glucokinase-like enzyme carries out glucose phosphorylation in capillaries of normal and spontaneously hyperglycemic rabbits. Biochem Med Metab Biol. 49:1993;326-337.
4. Iannello S., Campione R., Volpicelli G., Belfiore F. Rabbit optic nerve phosphorylates glucose through a glucokinase-like enzyme. Studies in normal and spontaneously hyperglycemic animals Biochem Med Metab Biol. 53:1994;122-129.
5. Iannello S., Campione R., Volpicelli G., Belfiore F. Rabbit lens and retina phosphorylate glucose through a glucokinase-like enzyme. Study in normal and spontaneously hyperglycemic animals J Diab Comp. 10:1996;68-77.
6. Grossbard L., Schimke R.T. Multiple hexokinases of rat tissues. Purification and comparison of soluble forms. J Biol Chem. 241:1966;3546-3560.
7. Bedoya F.J., Wilson J.M., Ghosh A.K., Finegold D., Matschinsky F.M. The glucokinase glucose sensor in human pancreatic islet tissue. Diabetes. 35:1986;61-67.
8. Engerman R.L., Kern T.S. Hyperglycemia as a cause of diabetic retinopathy. Metabolism. 35(suppl 1):1986;20-23.
9. Marano C.W., Matschinsky F.M. Biochemical manifestations of diabetes mellitus in microscopic layers of the cornea and retina. Diabetes Metab Rev. 5:1989;1-15.
10. Sochor M., Baquer N.Z., Hothersall J.S., McLean P. Effect of experimental diabetes on the activity of hexokinase isoenzymes in tissues of the rat. Biochem Int. 22:1990;467-474.
11. Winegrad A.I. Does a common mechanism induce the diverse complications of diabetes? Banting Lecture 1986. Diabetes. 36:1987;396-406.
12. Scott T.M., Foote J., Peat B., Galway G. Vascular and neural changes in the rat optic nerve following induction of diabetes with streptozotocin. J Anat. 144:1986;145-152.
13. Murphy E.D., Anderson J.W. Tissue glycolytic and gluconeogenic enzyme activities in mildly and moderately diabetic rats. Influence of tolbutamide administration Endocrinology. 94:1974;27-34.
14. Parry M.J., Walker D.G. Purification and properties of adenosine 5′-triphosphate-D-glucose 6-phosphotransferase from rat liver. Biochem J. 99:1966;266-274.
15. Davidson A.L., Arion W.J. Factors underlying significant underestimation of glucokinase activity in crude liver extracts. Physiological implications of higher cellular activity Arch Biochem Biophys. 253:1987;156-167.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
17. Dvornik D., Simard-Duquesne N., Greselin E., Dubuc J., Hicks D.R., Kraml M. AY-27,773. A novel orally active inhibitor of aldose reductase Diabetes. 32(suppl 1):1983;164A.
18. Dvornik D., Millen J., Hicks D.R., Kraml M. Tolrestat pharmacokinetics in rat peripheral nerve. J Diab Comp. 8:1994;18-26.
19. Benfield P. Aldose reductase inhibitors and late complications of diabetes. Drugs. 32(suppl 2):1986;43-55.
20. Notvest R.R., Inserra J.J. Tolrestat, an aldose reductase inhibitor, prevents nerve dysfunction in conscious diabetic rats. Diabetes. 36:1987;500-504.
21. Frank R.N. Aldose reductase inhibition. The chemical key to control of diabetic retinopathy? Arch Ophthalmol. 108:1990;1229-1231.
22. Robison W.G. Jr., Tillis T.N., Laver N., Kinoshita J.H. Diabetes-related hystopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res. 50:1990;355-366.
23. Reddy V.N., Lin L.R., Giblin F.J., Lou M., Kador P.F., Kinoshita J.H. The efficacy of aldose reductase inhibitors on polyol accumulation in human lens and retinal pigment epithelium in tissue culture. J Ocul Pharmacol. 8:1992;43-52.
24. Greene D.A., Sima A.A. Effects of aldose reductase inhibitors on the progression of nerve damage. Diabet Med. 10(suppl 2):1993;31S-32S.
25. Tomlinson D.R. Aldose reductase inhibitors and the complications of diabetes mellitus. Diabet Med. 10:1993;214-230.
26. Nicolucci A., Carinci F., Graepel J.G., Hohman T.C., Ferris F., Lachin J.M. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Diabetes Care. 19:1996;1091-1096.
27. Terada M., Yasuda H., Kikkawa R., Shigeta Y. Tolrestat improves nerve regeneration after crush injury in streptozotocin-induced diabetic rats. Metabolism. 45:1996;1189-1195.
28. Lipinski C.A., Hudson N.J. Aldose reductase inhibitors as a new approach to the treatment of diabetic complications. Ann Rep Med Chem. 19:1984;169-177.
29. Kador P.F., Robison W.G. Jr., Kinoshita J.H. The pharmacology of aldose reductase inhibitors. Ann Rep Pharmacol Toxicol. 25:1985;691-714.
30. Simard-Duquesne N., Greselin E., Dubuc J., Dvornik D. The effects of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats. Metabolism. 34:1985;885-892.
31. Raskin P., Rosenstock J., Challis P., Ryder S., Mullane J.F., Gonzalez R., Hicks D., Smith T., Dvornik D. Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. Clin Pharmacol Ther. 38:1985;625-630.
32. Kemper C., Dvornik D. Prevention of neural myoinositol depletion in diabetic rats by aldose reductase inhibition with tolrestat. Proc Soc Exp Biol Med. 182:1986;505-510.
33. Williamson J.R., Ostrow E., Eades D., Chang K., Allison W., Kilo C., Sherman W.R. Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor. J Clin Invest. 85:1990;1167-1172.
34. Chibber R., Molinatti P.A., Wong J.S., Mirlees D., Kohner E.M. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes. 43:1994;758-763.
35. Greene D.A. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy. J Diab Comp. 6:1992;35-38.
36. Sima A.A., Greene D.A., Brown M.B., Hohman T.C., Hicks D., Graepel G.J., Bochenek W.J., Beg M., Gonen B. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group. J Diab Comp. 7:1993;157-169.
37. Boulton A.J., Levin S., Comstock J. A multicentre trial of the aldose reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 33:1990;431-437.
38. Greene D.A., Bochenek W., Haraty Y., Sima A.A.F., Hohman T., Hicks D., Beg M., Gonen B., the Tolrestat Study Group Biochemical and morphometric response to tolrestat in human diabetic nerve. Diabetologia. 33:1990;92A.
39. van Gerven J.M.A., Lemkes H.H.P.J., van Dijk J.G., Padberg G.W.A.M., Krans H.M.J. Long term effects of tolrestat, an aldose reductase inhibitor, on symptomatic diabetic sensory polyneuropathy. Diabetologia. 33:1990;320A.
40. Ziegler D. Diagnosis and management of diabetic peripheral neuropathy. Diabet Med. 13(suppl 1):1996;S34-S38.
41. Albers J.W., Brown M.B., Sima A.A., Greene D.A. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial. The effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial Neurology. 46:1996;85-91.
42. Albers J.W., Brown M.B., Sima A.A., Greene D.A. Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the Early Diabetes Intervention Trial (EDIT). Tolrestat Study Group for EDIT (Early Diabetes Intervention Trial). Muscle Nerve. 19:1996;140-146.
43. Ryder S., Sarokhan B., Shand D.G., Mullane J.F. Human safety profile of Tolrestat. An aldose reductase inhibitor Drug Dev Res. 11:1987;131-143.
44. Engerman R., Bloodworth J.M.B. Jr., Nelson S. Relationship of microvascular disease in diabetes and metabolic control. Diabetes. 26:1977;760-769.
45. Raskin P. Diabetic regulation and its relationship to microangiopathy. Metabolism. 27:1978;235-252.
46. Hanssen K.F., Dahl-Jorgensen K., Lauritzen T., Feldt-Rasmussen B., Briuchmann-Hansen O., Deckert T. Diabetic control and microvascular complications. The near-normoglycaemia experience Diabetologia. 26:1986;677-684.
47. Gabbay K.H. Hyperglycemia, polyol metabolism and complications of diabetes mellitus. Annu Rev Med. 26:1975;521-536.
48. Kador P.F., Akagi Y., Kinoshita J.H. The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism. 35(suppl 1):1986;15-19.
49. Yeh L.-A., Rafford C.E., Beyer T.A., Hutson N.J. Effects of the aldose reductase inhibitor Sorbinil on the isolated cultured rat lenses. Metabolism. 35(suppl 1):1986;4-9.
50. Gunn R.B., Gunn H.B. Inhibition of erythrocyte anion exchange by tolrestat, an inhibitor of aldose reductase. Metabolism. 38:1989;801-804.
51. Sochor M., Kunjara S., McLean P. The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats. Biochem Pharmacol. 37:1988;3349-3356.
52. Obrosova I., Faller A., Burgan J., Ostrow E., Williamson J.R. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats. Effect of an aldose reductase inhibitor Curr Eye Res. 16:1997;34-43.
53. Wermuth B., Burgisser H., Bohren K., Von Wartburg J.P. Purification and characterization of human-brain aldose reductase. Eur J Biochem. 127:1982;279-284.
54. Srivastava S.K., Ansari N.H., Hair G.A., Awasthi H.S., Das B. Activation of human erythrocyte, brain, aorta, muscle and ocular tissue aldose reductase. Metabolism. 35(suppl 1):1986;114-118.